We therefore conclude that the therapy with both insulin and glucagon performs better than the therapy with only insulin, as the risks for both hypoglycemia and hyperglycemia are reduced and glucose fluctuations are suppressed. The gene discussed is INS; the disease is Hypoglycemia.